drugset / Trial / NCT02487550

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

NCT02487550

Phase 2 Not yet recruiting 1200 enrolled The First People's Hospital of Changzhou
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

Timeline

Start
2015-08
Primary completion
2028-07
Completion
2030-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CIK cells Cell therapy Intravenous
Subject Dendritic cells Cell therapy Other
Subject IFN-α Unknown Intravenous
Subject aldesleukin Protein / enzyme biologic Intravenous

Indications